绝经后乳腺癌芳香化酶抑制剂治疗后使用来曲唑(NRG肿瘤学/NSABP B-42):一项随机、双盲、安慰剂对照的3期试验
这项随机、双盲、安慰剂对照3期试验在158个中心纳入绝经后激素受体阳性早期乳腺癌患者,这些患者在接受约5年芳香化酶抑制剂为基础的治疗后无病。患者随机接受5年来曲唑或安慰剂。来曲唑未显著改善无病生存期(HR 0.85,95%CI 0.73-0.999,p=0.048,未达预设显著性水平0.0418)。
要点
- 来曲唑组无病生存事件292例,安慰剂组339例,HR 0.85(95%CI 0.73-0.999),p=0.048,未达预设显著性水平0.0418。
- 7年无病生存率来曲唑组84.7%(95%CI 82.9-86.4),安慰剂组81.3%(95%CI 79.3-83.1)。
- 常见3级不良事件为关节痛和背痛,4级不良事件少见。
核心结论
- 在5年芳香化酶抑制剂为基础的治疗后,与安慰剂相比,5年来曲唑治疗未显著延长无病生存期。
- 在向早期乳腺癌患者推荐延长来曲唑治疗前,需要仔细评估潜在的风险和获益。
研究设计与样本
- 随机、双盲、安慰剂对照的3期试验,在美国、加拿大和爱尔兰的158个中心进行。
- 纳入绝经后I-IIIA期激素受体阳性乳腺癌患者,这些患者在接受芳香化酶抑制剂或他莫昔芬后序贯芳香化酶抑制剂约5年治疗后无病。
- 患者按1:1随机分配接受5年来曲唑(2.5 mg口服每日一次)或安慰剂,随机化按病理淋巴结状态、既往他莫昔芬使用和腰椎、全髋或股骨颈最低骨密度T值分层。
- 主要终点为无病生存期,定义为从随机化到乳腺癌复发、第二原发恶性肿瘤或死亡的时间,按意向治疗分析。
- 为调整既往中期分析,无病生存期的双侧统计学显著性水平设定为0.0418。
主要发现
- 2006年9月28日至2010年1月6日间,3966例患者被随机分配接受来曲唑(n=1983)或安慰剂(n=1983)。
- 3903例患者有无病生存期分析的随访信息,中位随访6.9年(IQR 6.1-7.5)。
- 安慰剂组报告339例无病生存事件,来曲唑组报告292例无病生存事件;风险比0.85,95%CI 0.73-0.999;p=0.048。
- 7年无病生存率估计值:安慰剂组81.3%(95%CI 79.3-83.1),来曲唑组84.7%(95%CI 82.9-86.4)。
- 最常见的3级不良事件为关节痛(安慰剂组1933例中47例[2%] vs 来曲唑组1941例中50例[3%])和背痛(44例[2%] vs 38例[2%]);安慰剂组最常见的4级不良事件为血栓栓塞事件(8例[<1%]),来曲唑组最常见的4级不良事件为尿路感染、低钾血症和左心室收缩功能障碍(各4例[<1%])。
临床怎么用
- 作者认为,在向早期乳腺癌患者推荐延长来曲唑治疗前,需要仔细评估潜在的风险和获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer. METHODS: This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo. Randomisation was stratified by pathological node status, previous tamoxifen use, and lowest bone mineral density T score in the lumbosacral spine, total hip, or femoral neck. The primary endpoint was disease-free survival, defined as time from randomisation to breast cancer recurrence, second primary malignancy, or death, and was analysed by intention to treat. To adjust for previous interim analyses, the two-sided statistical significance level for disease-free survival was set at 0·0418. This study is registered with ClinicalTrials.gov, number NCT00382070, is active, and is no longer enrolling patients. FINDINGS: Between Sept 28, 2006, and Jan 6, 2010, 3966 patients were randomly assigned to receive letrozole (n=1983) or placebo (n=1983). Follow-up information was available for 3903 patients for the analyses of disease-free survival. Median follow-up was 6·9 years (IQR 6·1-7·5). Letrozole treatment did not significantly improve disease-free survival (339 disease-free survival events were reported in the placebo group and 292 disease-free survival events were reported in the letrozole group; hazard ratio 0·85, 95% CI 0·73-0·999; p=0·048). 7-year disease-free survival estimate was 81·3% (95% CI 79·3-83·1) in the placebo group and 84·7% (82·9-86·4) in the letrozole group. The most common grade 3 adverse events were arthralgia (47 [2%] of 1933 patients in the placebo group vs 50 [3%] of 1941 patients in the letrozole group) and back pain (44 [2%] vs 38 [2%]). The most common grade 4 adverse event in the placebo group was thromboembolic event (eight [<1%]) and the most common grade 4 adverse events in the letrozole group were urinary tract infection, hypokalaemia, and left ventricular systolic dysfunction (four [<1%] each). INTERPRETATION: After 5 years of aromatase inhibitor-based therapy, 5 years of letrozole therapy did not significantly prolong disease-free survival compared with placebo. Careful assessment of potential risks and benefits is required before recommending extended letrozole therapy to patients with early-stage breast cancer. FUNDING: National Cancer Institute, Korea Health Technology R&D Project, Novartis.
引用
- Mamounas EP, Bandos H, Lembersky BC, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018. PMID: 30509771. doi:10.1016/S1470-2045(18)30621-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。